Posts

Microsoft abandons older Windows

Thousands of companies and individuals could face security headaches and inconvenience as Microsoft stops selling some of its older products.

It has announced it is withdrawing products such as Windows 98, Windows NT 4 and Outlook 2000.

The decision was made because the programs contain code outlawed under a legal deal with rival Sun Microsystems

Bertelsmann faces $1bn pay-out

Music giant Bertelsmann may have to pay up to $1bn to two internet businessmen after losing a breach of contract lawsuit.

A California jury awarded the payment to two men who helped put together Bertelsmann’s 1995 merger with web portal AOL Europe.

Bertelsmann later sold half its stake in AOL Europe to Time Warner for $6

Alaska well explosion may cost BP $2.5 mln fine

ANCHORAGE, Alaska, Dec 15 (Reuters) – An Alaska agency has notified BP Exploration (Alaska) Inc., a unit of BP Plc , that it intends to fine the company $2

Questionable Advertising

Eurostar, the cross-Channel train operator, has called on regulators to scrutinise adverts by British Airways that it says are misleading.

Guillame Pepy, Eurostar’s boss, has asked France’s competition and anti-fraud body, the DGCCRF, to investigate ads offering cheap flights between Paris and London.

The complaint is about French ads that offer customers “London at 29

Ordered to pull misleading adverts

The US government has ordered a drug giant to quit running a series of radio and newspaper ads that call the allergy spray Flonase a cost-effective alternative to pricey allergy pills.

The ad campaign urged allergy sufferers to ask their doctor about Flonase, a nasal spray, instead of antihistamine pills like Allegra and Zyrtec. Flonase maker GlaxoSmithKline began the ads shortly after insurance companies raised prices for the pills this spring

FDA tells Glaxo to pull misleading Flonase ads

U.S. regulators ordered GlaxoSmithKline Plc to pull radio and print advertisements for its Flonase prescription nasal allergy spray that the Food and Drug Administration deemed misleading

Martha Stewart appears in Court

The domestic style setter is facing federal obstruction of justice charges, related to an investigation of her December 2001 sale of almost 4,000 shares of biotech firm ImClone Systems before bad news about one of its key drugs was revealed to the public. Stewart and her attorneys have denied any wrongdoing in the case.

Stewart, whose June 4 arraignment in court was a media circus, is heading into court for what is known as a status conference, in which lawyers on the two sides of the case can raise issues before the judge and discuss a schedule